INTRODUCTION {#sec1}
============

Human respiratory syncytial virus (RSV) is a leading viral cause of severe respiratory infection during infancy and early childhood and among immunocompromised populations ([@B1], [@B2]). Globally, the virus is estimated to be responsible for 30 million episodes of acute lower respiratory tract infections (RTIs) and more than 50,000 deaths annually in children under 5 years of age ([@B3]). RSV infections throughout the world consistently occur as annual or biennial epidemics, and persons of all ages can be infected with diverse clinical outcomes ranging from mild upper RTIs to severe pneumonia or bronchiolitis ([@B2], [@B4]). A vaccine against RSV is not yet available ([@B5]). Careful analyses of RSV molecular epidemiology, evolution, and transmission are essential for defining the circulating viruses, for characterizing antigenic variation, and for tracking transmission patterns. The outcome of these studies can support new strategies for RSV control and vaccine use and development.

It has long been known that children suffer repeated RSV infections throughout life ([@B6], [@B7]). The ability of the virus to continue to infect previously exposed individuals is thought to be linked to an ability to bypass preexisting immune responses ([@B8]). Sequence variation in attachment (G) protein in consecutive years ([@B9]) is thought to be part of this mechanism; also, the global existence of two groups, A and B, and their alternating infection incidences may play a role ([@B10], [@B11]). The transmissibility of RSV group A (RSVA) is estimated to be slightly higher than that of RSV group B (RSVB) ([@B12]), and RSVA infections are more frequent than RSVB infections ([@B12]). An additional important feature of RSV infection is the apparently rapid global dispersion of new RSV variants ([@B13]). Indeed, genetically similar viruses cluster more by time than by location, suggesting rapid global movement of new variants ([@B14]). RSV molecular pathology and epidemiology have been reviewed in detail elsewhere ([@B2], [@B4], [@B15], [@B16]).

Historically, RSV molecular epidemiology has focused on the 900-bp region encoding the G protein ([@B15], [@B17]). The G protein together with the fusion (F) protein are important targets of human protective antibody responses ([@B8], [@B15]), with changes in this region thought to be driven by pressure to avoid host immune responses. Although studies of the sequence variability of RSV have concentrated on G gene variability, given the rapid infection pace but relatively low evolutionary rate of RSV, transmission studies over short periods require the stronger evolutionary signal provided by the full virus genome sequence (15,200 nucleotides \[nt\]: 11 open reading frames \[ORFs\] and noncoding regions). There is also a need to understand the nature of variation of immune targets other than the G protein. Advances in primer design, sequencing technology, and sequence assembly algorithms now allow full-genome sequencing for a number of viruses, including RSV ([@B18][@B19][@B23]), norovirus ([@B24]), and Middle East respiratory syndrome (MERS) coronavirus ([@B25], [@B26]).

The current work describes RSV genome evolution across a set of clinical samples collected from children who presented with severe RSV disease in a rural coastal Kenyan hospital using a novel RSV whole-genome sequencing (WGS) approach optimized for small amounts of clinical diagnostic samples. The sequence data provide an update of the genome-wide diversity of circulating RSV strains in this part of Kenya, including both RSVA and RSVB and the recently reemerged group B genotype GB3 ([@B27]). The novel genomes support previous conclusions on patterns of local RSV variation relative to global RSV diversity and reveal a significant difference in local evolution of RSVA versus RSVB.

MATERIALS AND METHODS {#sec2}
=====================

Primer design. {#sec2-1}
--------------

All RSV sequences available (August 2012) with lengths of \>14,000 nt were collected and sorted by group, yielding 138 RSVA and 38 RSVB genomes. The sequences for each group were pooled and sliced into 33-nt strings with a 1-nt step size. The 33-mers were filtered to remove sequences with ambiguous nucleotides, and the frequency of each sequence within the set was determined. The 33-nt sequences were then trimmed to a calculated melting temperature (*T~m~*) of 58°C, discarding sequences mapping to human rRNA, with GC contents of \<30% or \>65%, or with a single nucleotide frequency of \>60%. The RSV genome was divided into six 3-kb segments overlapping by 300 nt. All sequences were mapped to an RSVA or RSVB reference strain, and the two most frequent primers mapping within 300 nt of the end of each amplicon were selected. The reverse complement of the downstream sequences was prepared. To ensure amplification of the far ends of the genomes, two additional primers were included from the 5′- and 3′-terminal genomic regions. A summary of the primer sequences and their predicted target sequences across all known RSV genomes is presented in [Table 1](#T1){ref-type="table"}.

###### 

Summary of RSV primers used in this study

  Target   Primer     Sequence (5′ to 3′)                 Strand   Position[^*a*^](#T1F1){ref-type="table-fn"}   *T~m~* (°C)[^*b*^](#T1F2){ref-type="table-fn"}   \% with 0 MM[^*c*^](#T1F3){ref-type="table-fn"}   \% with 0--3 MM[^*d*^](#T1F4){ref-type="table-fn"}
  -------- ---------- ----------------------------------- -------- --------------------------------------------- ------------------------------------------------ ------------------------------------------------- ----------------------------------------------------
  RSVA     rsvas      ACGCGAAAAAATGCGTACAAC               Plus     1                                             57.13                                            18.28                                             18.97
  RSVA     rsva52     TGTGCATGTTATTACAAGTAGTGATATTTG      Plus     266                                           56.96                                            95.52                                             98.97
  RSVA     rsva50     GCATGTTATTACAAGTAGTGATATTTGCC       Plus     269                                           57.51                                            95.17                                             98.97
  RSVA     rsva117    ATAAGAGATGCCATGGTTGGTTTAAGA         Plus     2849                                          58.44                                            95.86                                             100.00
  RSVA     rsva86     AAGAGATGCCATGGTTGGTTTAAGA           Plus     2851                                          58.43                                            95.86                                             100.00
  RSVA     rsva175    TTCTCTTAAACCAACCATGGCATCT           Minus    2878                                          58.43                                            95.86                                             100.00
  RSVA     rsva39     CTTCTCTTAAACCAACCATGGCATC           Minus    2879                                          58.22                                            95.86                                             100.00
  RSVA     rsva1820   GCAGCATATGCAGCAACAATC               Plus     5207                                          56.95                                            93.79                                             98.97
  RSVA     rsva1914   CAGCATATGCAGCAACAATCCAA             Plus     5208                                          58.32                                            93.10                                             98.62
  RSVA     rsva1644   CAACTCCATTGTTATTTGCCCC              Minus    5674                                          56.05                                            89.66                                             100.00
  RSVA     rsva1688   CAACTCCATTGTTATTTGCCCCA             Minus    5674                                          57.54                                            89.66                                             100.00
  RSVA     rsva704    ATGTGTTGCCATGAGCAAACTC              Plus     7893                                          57.95                                            91.03                                             100.00
  RSVA     rsva731    GCCATGAGCAAACTCCTCACT               Plus     7900                                          58.49                                            71.38                                             99.31
  RSVA     rsva341    TTGTCAGGTAGTATCATTATTTTTGGCATG      Minus    8196                                          58.53                                            98.97                                             99.31
  RSVA     rsva312    AGGATATTTGTCAGGTAGTATCATTATTTTTGG   Minus    8203                                          58.08                                            98.97                                             100.00
  RSVA     rsva374    AAGAGAACTCAGTGTAGGTAGAATGTTT        Plus     10360                                         57.89                                            96.55                                             100.00
  RSVA     rsva350    AGAACTCAGTGTAGGTAGAATGTTTG          Plus     10363                                         56.64                                            96.55                                             100.00
  RSVA     rsva497    GCTTGATTGAATTTGCTGAGATCTGT          Minus    10620                                         58.44                                            95.52                                             100.00
  RSVA     rsva539    ATGCTTGATTGAATTTGCTGAGATCTG         Minus    10622                                         58.68                                            95.52                                             100.00
  RSVA     rsva1220   GATTGGGTGTATGCATCTATAGATAACAAG      Plus     12386                                         57.94                                            95.86                                             99.31
  RSVA     rsva1232   ATTGGGTGTATGCATCTATAGATAACAAG       Plus     12387                                         57.17                                            95.86                                             99.31
  RSVA     rsva364    TTATATATCCCTCTCCCCAATCTTTTTCAAA     Minus    13070                                         58.32                                            96.21                                             100.00
  RSVA     rsva385    ATCAGTTATATATCCCTCTCCCCAATCTT       Minus    13075                                         58.46                                            96.21                                             100.00
  RSVA     rsva4066   GTTGTATAACAAACTACCTGTGATTTTAATCAG   Minus    14983                                         57.95                                            88.97                                             99.31
  RSVA     rsva5632   TAACTATAATTGAATACAGTGTTAGTGTGTAGC   Minus    15063                                         57.95                                            29.31                                             95.17
  RSVA     rsvae      ACGAGAAAAAAAGTGTCAAAAACTAATA        Minus    15223                                         55.09                                            17.59                                             18.28
  RSVB     rsvbs      ACGCGAAAAAATGCGTACTACA              Plus     1                                             57.56                                            43.14                                             43.14
  RSVB     rsvb3      TGGGGCAAATAAGAATTTGATAAGTGC         Plus     44                                            58.58                                            48.04                                             54.90
  RSVB     rsvb1021   GGGGCAAATAAGAATTTGATAAGTGCTATT      Plus     45                                            58.75                                            47.06                                             54.90
  RSVB     rsvb33     ATATTAGGAATGCTCCATACATTAGTAGTTG     Plus     2777                                          57.21                                            88.24                                             100.00
  RSVB     rsvb71     TAAGAGATGCTATGGTTGGTCTAAGAGA        Plus     2841                                          58.69                                            90.20                                             100.00
  RSVB     rsvb50     AGTCTTGCCATAGCCTCTAACCT             Minus    2937                                          58.57                                            93.14                                             100.00
  RSVB     rsvb95     CCATTTTTTCGCTTTCCTCATTCCTA          Minus    2963                                          58.14                                            95.10                                             100.00
  RSVB     rsvb7884   AGTATATGTGGCAACAATCAACTCTG          Plus     5202                                          57.48                                            81.37                                             100.00
  RSVB     rsvb7996   TATGTGGCAACAATCAACTCTGC             Plus     5206                                          57.70                                            81.37                                             100.00
  RSVB     rsvb7442   GATGTGGAGGGCTCGGATG                 Minus    5548                                          57.92                                            75.49                                             100.00
  RSVB     rsvb7423   CCATGGTTATTTGCCCCAGATTTAAT          Minus    5662                                          57.87                                            77.45                                             99.02
  RSVB     rsvb3762   AGAGGTCATTGCTTGAATGGTAGAA           Plus     7642                                          57.98                                            93.14                                             100.00
  RSVB     rsvb3712   AAGAGCATAGACACTTTGTCTGAAATAAG       Plus     7762                                          57.89                                            77.45                                             100.00
  RSVB     rsvb3652   GCTTATGGTTATGCTTTTGTGGATATCTAAT     Minus    8130                                          58.41                                            89.22                                             98.04
  RSVB     rsvb3660   GCAATCATGCTTTCACTTGAGATCAA          Minus    8247                                          58.67                                            64.71                                             98.04
  RSVB     rsvb32     AAGAAGAGTACTAGAGTATTACTTGAGAGATAA   Plus     10236                                         57.04                                            90.20                                             100.00
  RSVB     rsvb52     AAATCCAAATCTTAGCAGAGAAAATGATAG      Plus     10412                                         56.70                                            96.08                                             100.00
  RSVB     rsvb47     CCATGCAGTTCATCTAATACATCACTG         Minus    10673                                         58.13                                            90.20                                             99.02
  RSVB     rsvb168    TGCATGTCTATATGTACATATTATTGTGACAAG   Minus    10746                                         58.25                                            91.18                                             99.02
  RSVB     rsvb651    ATCGACATTGTGTTTCAAAATTGCATAAG       Plus     12640                                         58.40                                            81.37                                             100.00
  RSVB     rsvb165    TTCAAAATTGCATAAGTTTTGGTCTTAGC       Plus     12653                                         58.06                                            88.24                                             100.00
  RSVB     rsvb27     TTAATGAACATATGATCAGTTATATACCCCTCT   Minus    13088                                         57.88                                            79.41                                             100.00
  RSVB     rsvb60     AACTTAAAACTGTGACAGCCTTTTATTCT       Minus    13325                                         58.08                                            89.22                                             100.00
  RSVB     rsvb1199   ATAGTACACTACCTGTTATTTTAATCAGCTTCT   Minus    14977                                         58.56                                            88.24                                             100.00
  RSVB     rsvb989    TATAGTACACTACCTGTTATTTTAATCAGCTTC   Minus    14978                                         57.57                                            88.24                                             100.00
  RSVB     rsvbe      ACGAGAAAAAAAGTGTCAAAAACTAATGT       Minus    15216                                         57.47                                            5.88                                              6.86

Primer mapping position in RSVA (GenBank accession number [FJ948820](FJ948820)) or RSVB (GenBank accession number [JQ582843](JQ582843)).

*T~m~* (melting temperature) calculated using a Python script that approximates the method of Breslauer et al. ([@B51]).

Percentage of full-length RSVA genomes (*n* = 290) or full-length RSVB genomes (*n* = 102) showing perfect homology to primer, i.e., 0 mismatches (MM).

Percentage of full-length RSVA genomes (*n* = 290) or full-length RSVB genomes (*n* = 102) showing the target sequence for the primer with up to 3 mismatches.

Clinical samples. {#sec2-2}
-----------------

Viral nucleic acid for sequencing was extracted from RSV-positive clinical specimens (nasopharyngeal swabs \[NPS\] or washes) collected from children under 5 years old admitted to the Kilifi District Hospital (KDH) with severe or very severe pneumonia between 2002 and 2012. RSV infection was diagnosed with an indirect immunofluorescence antibody technique (IFAT; Light Diagnostics). Details of the study that provided the samples sequenced in this study have been previously provided ([@B28]). Informed consent was obtained from a parent or guardian on behalf of each child before specimen collection, and the KEMRI Ethics Review Committee approved all protocols. Additional details on the samples are provided in [Table 2](#T2){ref-type="table"}.

###### 

Details for samples used in this study

  MiSeq      Age (mo)   Sample date (day-mo-yr)   Group   Length (nt)[^*a*^](#T2F1){ref-type="table-fn"}   Coverage[^*b*^](#T2F2){ref-type="table-fn"}   Present in G set[^*c*^](#T2F3){ref-type="table-fn"}   Present in F set[^*d*^](#T2F4){ref-type="table-fn"}   GenBank no.[^*e*^](#T2F5){ref-type="table-fn"}   ENA no.[^*f*^](#T2F6){ref-type="table-fn"}
  ---------- ---------- ------------------------- ------- ------------------------------------------------ --------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ------------------------------------------------ --------------------------------------------
  10028_10   0          07-Jan-02                 A       9,346                                            6,401                                         Yes                                                                                                         KP317918                                         ERR323212
  10028_11   6          27-Apr-02                 A       7,091                                            10,370                                                                                                                                                    KP317940                                         ERR323213
  10028_12   6          28-Jan-03                 A       9,776                                            5,692                                                                                               Yes                                                   KP317955                                         ERR323214
  11866_65   5          13-Feb-03                 A       12,151                                           7,347                                         Yes                                                   Yes                                                   KP317949                                         ERR438932
  11865_75   8          24-Mar-04                 A       14,985                                           12,283                                        Yes                                                   Yes                                                   KP317956                                         ERR438910
  10891_50   6          21-Jan-05                 A       5,396                                            3,554                                         Yes                                                   Yes                                                   KP317948                                         ERR376407
  10891_56   0          02-Feb-05                 A       5,396                                            2,369                                         Yes                                                   Yes                                                   KP317924                                         ERR376413
  9696_45    14         20-Feb-06                 A       14,778                                           3,830                                         Yes                                                   Yes                                                   KP317944                                         ERR303303
  10891_57   1          23-Feb-06                 A       14,841                                           4,640                                         Yes                                                   Yes                                                   KP317942                                         ERR376414
  10891_58   0          29-Mar-06                 A       8,864                                            6,016                                                                                                                                                     KP317943                                         ERR376415
  10891_59   3          04-Jan-07                 A       11,496                                           5,316                                                                                               Yes                                                   KP317937                                         ERR376416
  10891_60   1          05-Jan-07                 A       14,791                                           4,454                                         Yes                                                   Yes                                                   KP317926                                         ERR376417
  10891_51   0          07-Mar-08                 A       14,967                                           4,882                                         Yes                                                   Yes                                                   KP317933                                         ERR376408
  10891_52   11         17-Mar-08                 A       5,636                                            1,201                                         Yes                                                                                                         KP317931                                         ERR376409
  10899_38   1          22-Feb-09                 A       14,854                                           8,478                                         Yes                                                   Yes                                                   KP317950                                         ERR381723
  10899_40   4          26-Jan-10                 A       10,113                                           13,351                                                                                              Yes                                                   KP317916                                         ERR381725
  10899_41   18         10-Feb-10                 A       14,713                                           12,405                                        Yes                                                   Yes                                                   KP317935                                         ERR381726
  11864_54   3          29-Apr-10                 A       14,716                                           7,071                                         Yes                                                   Yes                                                   KP317936                                         ERR438905
  11862_33   3          26-Aug-10                 A       14,719                                           8,961                                         Yes                                                   Yes                                                   KP317921                                         ERR438868
  11864_53   1          25-Mar-11                 A       14,735                                           6,891                                         Yes                                                   Yes                                                   KP317951                                         ERR438904
  11862_28   28         13-Apr-11                 A       15,214                                           10,434                                        Yes                                                   Yes                                                   KP317920                                         ERR438864
  11862_29   4          23-Mar-12                 A       14,950                                           12,922                                        Yes                                                   Yes                                                   KP317953                                         ERR438865
  11862_32   14         30-Apr-12                 A       7,197                                            6,180                                                                                                                                                     KP317947                                         ERR438867
  9697_16    10         06-Jul-02                 B       15,040                                           5,419                                         Yes                                                   Yes                                                   KP317939                                         ERR303322
  9697_10    8          13-Jan-03                 B       9,790                                            6,853                                                                                               Yes                                                   KP317930                                         ERR303316
  10140_1    46         02-Apr-04                 B       12,034                                           12,174                                        Yes                                                   Yes                                                   KP317919                                         ERR331021
  9697_7     10         22-Dec-04                 B       15,080                                           4,480                                         Yes                                                   Yes                                                   KP317925                                         ERR303313
  9697_6     2          25-Dec-04                 B       14,998                                           6,523                                         Yes                                                   Yes                                                   KP317954                                         ERR303312
  9697_5     1          27-Jan-06                 B       15,234                                           3,682                                         Yes                                                   Yes                                                   KP317917                                         ERR303311
  9465_10    23         27-Feb-09                 B       14,995                                           16,190                                        Yes                                                   Yes                                                   KP317938                                         ERR303268
  9465_11    31         13-Feb-10                 B       15,004                                           11,722                                        Yes                                                   Yes                                                   KP317941                                         ERR303269
  9465_12    22         06-Apr-10                 B       15,260                                           14,855                                        Yes                                                   Yes                                                   KP317932                                         ERR303270
  9465_6     17         09-May-10                 B       15,333                                           13,719                                        Yes                                                   Yes                                                   KP317952                                         ERR303264
  9465_7     3          01-Feb-11                 B       15,233                                           14,182                                        Yes                                                   Yes                                                   KP317927                                         ERR303265
  9465_8     2          14-Apr-11                 B       15,323                                           15,367                                        Yes                                                   Yes                                                   KP317945                                         ERR303266
  9465_9     1          08-Jul-11                 B       15,237                                           14,709                                        Yes                                                   Yes                                                   KP317928                                         ERR303267
  9465_3     8          14-Jan-12                 B       14,995                                           12,378                                        Yes                                                   Yes                                                   KP317946                                         ERR303261
  9465_1     19         13-Feb-12                 B       15,233                                           12,994                                        Yes                                                   Yes                                                   KP317934                                         ERR303259
  9465_4     14         01-Mar-12                 B       15,179                                           14,802                                        Yes                                                   Yes                                                   KP317923                                         ERR303262
  10911_9    1          23-Mar-12                 B       14,977                                           12,504                                        Yes                                                   Yes                                                   KP317929                                         ERR376442
  9465_2     5          16-May-12                 B       14,941                                           12,906                                        Yes                                                   Yes                                                   KP317922                                         ERR303260

Final sequence length obtained from *de novo* assembly of short read data (see Materials and Methods).

Coverage calculated by mapping all reads to final assembled contig. Coverage was calculated as the number of mapped reads/(length of the genome fragment/129).

Samples yielding sufficient sequence for G region analysis ([Fig. 5](#F5){ref-type="fig"}).

Samples yielding sufficient sequence for F region analysis ([Fig. 5](#F5){ref-type="fig"}).

The final genome data were deposited in GenBank with the indicated accession numbers.

Short-read data available at European Nucleotide Archive (<http://www.ebi.ac.uk/ena>).

RNA extraction, RT, and PCR. {#sec2-3}
----------------------------

Viral RNA was extracted with the QIAmp extraction kit (Qiagen, United Kingdom) from a starting NPS specimen volume of 140 μl and final elution volume of 60 μl. Reverse transcription (RT) of RNA molecules was performed with the forward primers for each of the six amplicons. A separate RT reaction was performed for each amplicon. Typically, the 20-μl reaction mixture contained 2 μl of sample RNA. A 5-μl aliquot of the resulting cDNA was used in each 25-μl PCR mixture. The PCR mixture was incubated at 98°C for 30 s, followed by 40 cycles of 98°C for 10 s, 53°C for 30 s, and 72°C for 3.0 min and a final extension of 72°C for 10.0 min. Following PCR, aliquots of the products were run on a 0.6% agarose gel to monitor amplification success, and the products from the 6 reactions for each sample were pooled for Illumina library preparation.

Deep sequencing. {#sec2-4}
----------------

Sequencing of the pooled amplicons was performed with Illumina MiSeq. Samples were multiplexed at 15 to 20 per MiSeq run and processed as paired-end reads (2 × 149 nt), generating approximately 1.5 million reads per sample. Raw sequence data were processed with QUASR ([@B29]) to remove low-quality (\< median Phred 35) and adapter-containing reads, and *de novo* assembly with SPAdes ([@B30]) was performed. RSV contigs were identified by BLASTN analysis, and low-coverage contigs were excluded. Where necessary, partial but overlapping genome contigs were combined using Sequencher (v5.2.4). All final viral genomes were examined for appropriate assembly based on length and the presence of the expected intact RSV open reading frames.

Protein changes. {#sec2-5}
----------------

After sorting by virus group (RSV group A or B), the genomic region under investigation was translated, the protein sequence was aligned using MAFFT ([@B31]), and protein differences from the consensus sequence of the group were visualized and quantitated using Python scripts.

Reference data set. {#sec2-6}
-------------------

A comprehensive RSV genome data set was generated from the GenBank database using as a starting set all reported RSV genomes. The search was conducted on 28 September 2014 using the search term "txid11250 \[Organism\]) AND 13500\[SLEN\]: 17000\[SLEN\]." Genomes with multiple ambiguous bases, lacking country of detection or date of collection (year), or from patent depositions were excluded. The newly sequenced Kilifi RSV genomes for each group were combined with those from GenBank in the subsequent analysis. Thinned representative reference sets were prepared by using the usearch algorithm ([@B32]).

Phylogenetic analyses. {#sec2-7}
----------------------

Phylogenetic trees of the genome sequences and selected genomic regions were constructed using the Bayesian methods in MrBayes program v3.2.1 (<http://mrbayes.sourceforge.net/index.php>) under the general time reversible model of evolution. RSVA and RSVB were analyzed separately using both the total data set and the thinned data sets. The viruses within the groups were assigned to genotypes based on the clustering pattern of the G ORF portion sequences with reference sequences representative of the previously described RSV genotypes: for RSVA, strains representing GA1-7, SAA1, and ON1, and for RSVB, strains representing GA1-4, SAB1-SAB4, and BA ([@B11], [@B33][@B34][@B35]). Phylogenetic trees were visualized in FigTree v1.4.2.

Evolutionary analyses. {#sec2-8}
----------------------

Nucleotide substitution rates and estimates for time to most recent common ancestor (tMRCA) were obtained from the usearch-thinned data sets, using uclust to remove genomes closer than ID 0.99 ([@B32]). The rates and tMRCA estimates were calculated in BEAST v1.7.5 ([@B36]) both for full genomes and for the individual ORFs.

Nucleotide sequence accession numbers. {#sec2-9}
--------------------------------------

The final set of RSV sequences was deposited in GenBank with the following accession numbers: [KP317916](KP317916) to [KP317956](KP317956).

RESULTS {#sec3}
=======

Two sets of reverse transcription and PCR primers were selected from all available RSVA and RSVB genomic sequence data based on frequency, location, and predicted PCR function (see [Table 1](#T1){ref-type="table"} for further details). The general pattern of primer sites and the locations of primer targets in RSVA and RSVB genomes are shown in [Fig. 1A](#F1){ref-type="fig"}. Actual PCR results are shown in [Fig. 1B](#F1){ref-type="fig"} for RSVA and RSVB samples, with PCR products of the expected size obtained for all 6 amplicons. These primers were used as part of a deep-sequencing process for RSV combining the full cDNA preparation and genome amplification, deep sequencing with Illumina MiSeq, and *de novo* assembly ([Fig. 1C](#F1){ref-type="fig"}) to generate 27 complete or nearly complete genomes (11 group A and 16 group B; median length, 14,990 nt; range, 14,666 to 15,232 nt). An additional number of samples yielded RSV contigs of \>5,000 nt in length, and these were also retained for further analysis. A summary of the genomic sequences in this study is provided in [Table 2](#T2){ref-type="table"}.

![(A) PCR primer target sites in RSVA and RSVB. The primer target sequences in representative RSVA (left) and RSVB (right) viruses were determined. Circular markers indicate positions of primer target sites in the test genome color-coded by number of mismatches with the primer; gray bars indicate lengths and positions of the predicted products. (B) Two examples of reverse transcription-PCR function. The DNA products of reverse transcription and PCR amplification of two samples were resolved by agarose gel electrophoresis and visualized by ethidium bromide staining. Sizes of some of the molecular size markers (in base pairs) are indicated to left of the gel. Lane m, molecular size markers; lanes 1 to 6, individual 2- to 3-kb RSV amplicons 1 to 6, respectively. (C) Flowchart of the RSV sequencing process.](zjv9990901930001){#F1}

RSV global phylogenetic clustering and placement of Kilifi genomes. {#sec3-1}
-------------------------------------------------------------------

The 27 Kilifi genomes were combined with RSVA and RSVB genomes from 16 countries from specimens collected between the years 1981 and 2013 (see Materials and Methods). The phylogenetic clustering is shown in [Fig. 2A](#F2){ref-type="fig"} (RSVA) and B (RSVB). RSVA forms 3 major clades: GA1 (including strains only from the United States), GA5 (with U.S. and global strains), and a clade with both GA2 and the ON1 viruses with a 72-nucleotide duplication in the G ORF ([@B33]), which included nearly all of the new Kilifi RSVA genomes (GA2_ON1). Multiple subclusters showing temporal clustering were detected within each of these clades.

![Phylogenetic analysis of the Kilifi RSVA and RSVB genomes. (A) MrBayes tree of representative global RSVA genome sequences together and the 11 novel Kilifi RSVA genome sequences. (B) MrBayes tree of representative global RSVB genome sequences and the 16 novel Kilifi RSVA genome sequences. Trees were inferred using the Bayesian methods in MrBayes (<http://mrbayes.sourceforge.net/index.php>) under the GTR model of evolution. The numbers next to the branches indicate the posterior probabilities. The Kilifi taxa are indicated in red font. Thinned global reference sets for RSVA and RSVB were prepared from all available RSV genomes clustering at 0.99% identity using uclust ([@B32]). See Materials and Methods for additional details.](zjv9990901930002){#F2}

Four clades were designated for the RSVB genomes, with BA containing the majority of the Kilifi sequences ([Fig. 2B](#F2){ref-type="fig"}). Clade GB1_GB4 included viruses detected in the United States between 1983 and 1991. Clades SAB1, GB3, and BA included viruses from multiple countries, including the Kilifi RSVB genomes. Similar to that for RSVA, the clustering was more temporal than geographical. Notably, the BA (Buenos Aires) clade viruses are characterized by the presence of a 60-nucleotide duplication within the G ORF. The 4 viruses within clade GB3 (3 from Kilifi and 1 from Germany) lacked the 60-nucleotide duplication. Neither RSVA nor RSVB genomes from Kilifi showed a monophyletic grouping. Instead, the Kilifi genomes were dispersed throughout the observed RSV evolution, clustering with contemporaneous genomes from the other countries. The phylogenetic tree topologies arising from whole-genome and G protein ORF sequences were highly similar (data not shown).

Comparison of genomes of viruses with identical G protein ORFs. {#sec3-2}
---------------------------------------------------------------

One motivation for developing full-genome methods was to increase the sensitivity for tracking RSV across short-term transmission chains. We asked if viruses identical in their G gene regions had differences elsewhere in their genomes. All RSV genomes (both GenBank or in the new data presented here) with identical G regions were identified, and the number of changes outside the G region were determined. Of 7 sets of viruses with identical G regions, all showed at least 1 but up to 9 nucleotide differences across the full genome ([Fig. 3](#F3){ref-type="fig"}). This increased resolution will be important in future studies examining RSV household transmission patterns to identify who acquires infection from whom.

![Comparison of RSVB genomes with identical G regions. Each panel represents a genome nucleotide alignment of RSVs that had identical G gene sequences. The G protein ORF portions of the genomes are highlighted gray across the panels and were identical. The vertical lines indicate where there are nucleotide substitutions occurring outside the G gene region between the genomes. The blue blocks indicate a gap in the sequence.](zjv9990901930003){#F3}

Estimation of RSV tMRCA and evolutionary rates. {#sec3-3}
-----------------------------------------------

Previous data on RSV evolution are largely derived from the G protein coding region. The full genomes generated in this study were combined with the GenBank reference data set, and these allowed an estimation of the global nucleotide substitution rates and the time to most recent common ancestor (tMRCA) for all the recently sequenced RSVA and RSVB viruses. These estimates were calculated for the different ORFs and the whole-genome sequences ([Fig. 4](#F4){ref-type="fig"}). The whole genomes provided more precise estimates of the MRCA, as observed from the interval of lower and upper 95% highest posterior density (HPD) compared to individual ORF data for the same set of viruses ([Fig. 4B](#F4){ref-type="fig"}).

![(A) Estimates of the nucleotide substitution rates for RSVA and RSVB in the individual ORFs and for the whole-genome sequence. (B) Estimates of tMRCA for RSVA and RSVB for the individual ORFs and for the whole-genome sequence. The analysis was undertaken using the usearch-thinned data sets (37 genome sequences for RSVA and 23 sequences for RSVB). The analysis was performed with BEAST ([@B36]).](zjv9990901930004){#F4}

The G protein ORF showed the highest nucleotide substitution rates for both RSVA and RSVB ([Fig. 4A](#F4){ref-type="fig"}). Elevated changes in G and M2-2 were observed previously using RSV full genomes from U.S. and European cohort data ([@B21]). Similar to the MRCA estimates, the whole-genome estimates for the evolutionary rates showed narrower confidence intervals than those from the individual ORFs. The two regions considered for vaccine targets, G and F, show a strikingly wide difference in rate, and this may be important for selecting conserved vaccine targets.

Changes in G and F coding regions, comparing local and global viruses. {#sec3-4}
----------------------------------------------------------------------

An important consideration for vaccine development is how representative a vaccine strain is for locally circulating viruses. The transmission patterns of a virus, the evolutionary rate of the virus, and patterns of human movement can strongly influence how quickly global strains reach a rural location. To address this important issue, the amino acid changes encoded by the RSV coding sequences observed in Kilifi were compared to the amino acid changes observed for all known RSV genomes from other parts of the world ([Fig. 5](#F5){ref-type="fig"}; [Table 3](#T3){ref-type="table"}).

![Kilifi versus global changes in the G, F, and NS2 proteins. (A) Kilifi compared to global G protein changes. For each group, the G protein sequences were identified as Kilifi or non-Kilifi (global) and aligned, and a consensus amino acid sequence was generated (at 60% level). The first portion shows the positions of O-linked (red) and N-linked (blue) glycosylation sites, the second portion shows general features of the G protein, and the third portion shows total changes (Kilifi plus global) at each position. The fourth portion shows amino acid differences in each G sequence from the consensus. Amino acid changes observed only in Kilifi are marked in red, and changes observed either globally or in the Kilifi are marked in gray. Gaps are not indicated. N-linked and O-linked glycosylation sites were determined using NetNGlyc 1.0 and NetOGlyc 3.1 ([@B46][@B47][@B48]). (B) Kilifi versus global F protein changes. Changes in F protein were determined and are depicted as in panel A. Known motifs of the F protein ([@B49]) include signal peptide (SP), heptad repeat C (HRC), 27-mer fragment (p27), putative fusion peptide (FP), heptad repeat A (HRA), domains 1 and 2 (Dom1&2), heptad repeat B (HRB), transmembrane domain (TM), and cytoplasm domain (CP). Antigenic sites I, II, and IV (ASI, ASII, and ASIV) are sites of neutralizing antibody binding ([@B40], [@B50]). (C) Kilifi versus global NS2 protein changes. Changes in NS2 protein were determined and are depicted as in panel A. Known motifs of the NS2 protein include the TRAF3-interacting domain (TRAF3-ID) and C-terminal tetrapeptide sequence (DLNP) ([@B43]).](zjv9990901930005){#F5}

###### 

Kilifi versus global evolution

  Protein    No. of distinct changes for all Kilifi and global viruses   No. of distinct changes in Kilifi viruses   No. (%) of distinct changes unique to Kilifi viruses[^*a*^](#T3F1){ref-type="table-fn"}
  ---------- ----------------------------------------------------------- ------------------------------------------- -----------------------------------------------------------------------------------------
  RSVA G     409                                                         68                                          7 (11.8)[^*b*^](#T3F2){ref-type="table-fn"}
  RSVB G     299                                                         70                                          30 (42.9)
  RSVA F     200                                                         45                                          9 (22.2)[^*c*^](#T3F3){ref-type="table-fn"}
  RSVB F     81                                                          19                                          13 (79.3)
  RSVA NS2   73                                                          18                                          3 (16.7)[^*d*^](#T3F4){ref-type="table-fn"}
  RSVB NS2   38                                                          16                                          13 (81.3)

Number of distinct amino acid changes observed in Kilifi and not in other parts of the world. "Distinct changes" means that the set of changes is reduced to a unique set with multiple occurrences of a change counted only once.

The *P* value for Fisher\'s exact test was \<0.01 for the number of location-specific distinct changes compared to total distinct changes for RSVA versus RSVB.

The *P* value for Fisher\'s exact test was \<0.05 for the number of location-specific distinct changes compared to total distinct changes for RSVA versus RSVB.

The *P* value for Fisher\'s exact test was \<0.05 for the number of location-specific distinct changes compared to total distinct changes for RSVA versus RSVB.

A large percentage of the changes observed in the RSVA G protein were also observed globally, with 88% of the changes seen in Kilifi RSVA G also observed in other parts of the world ([Table 3](#T3){ref-type="table"}). The Kilifi RSVB viruses appeared to have more local evolution, with only 60% of the observed changes in G shared with global viruses. With reference to the F protein, for Kilifi RSVA viruses, 80% of the observed changes were also found globally, while the Kilifi RSVB viruses showed a higher degree of local evolution, with only 20% of the observed changes specific to Kilifi viruses seen in other locations. To determine if this local evolution of RSVB was observed at other sites, the sequence data were stratified to other locations (the United States, Argentina, and Peru), but no significant local patterns were observed. This suggests that the isolation of the Kilifi site was more pronounced than for other sites. Alternatively, this may reflect more intense sampling of RSVB within a limited area.

The RSV envelope proteins are heavily glycosylated. More than 50% of the G protein mass can be carbohydrate ([@B37]), and the potential O-linked glycosylation sites (serine or threonine) comprise up to 30% of the G protein amino acid sequence ([@B38]). Changes toward or away from asparagine can be associated with a change in the overall glycosylation of the protein and could be associated with adaptive change to local immune responses. The G protein is subject to heavy O-linked glycosylation in the variable regions, with modification frequently on serine or threonine residues in the vicinity of a proline residue ([Fig. 5A](#F5){ref-type="fig"}). Nearly half of the observed changes in the in G protein affect S, T, or P residues (RSVA GA2 37/81 and RSVB 100/241). This is apparent when potential N- and O-linked glycosylation sites are marked on the G protein region ([Fig. 5](#F5){ref-type="fig"}) and is also facilitated by the single nucleotide changes that distinguish codons for these three amino acids.

In the RSVA G proteins, an N237D polymorphism observed in many of the viruses is within the site NTT and would remove a predicted N-linked glycosylation site. Tan et al. ([@B22]) also noted that the RSVA-GA2 group showed a frequent change in two predicted glycosylation sites (N237D and S242N). Within the RSVB viruses, 3 of 15 amino acid changes involve asparagine, but none of these changes are predicted N-linked glycosylation sites (Asn-Xaa-Ser/Thr). Changes in N-linked glycosylation areas are known to effect binding of human convalescent-phase sera to peptides ([@B39]).

The RSV F protein contains only 10 to 20% of its mass as carbohydrate, and this is attached exclusively via N-glycosidic bonds ([@B37]). For the RSVA viruses, 5 of the protein changes are to or away from asparagine. In RSVB, 3 changes involve asparagine; however, none of these are within predicted glycosylation sites. Many polymorphisms were observed in the F protein p27 domain ([Fig. 5B](#F5){ref-type="fig"}). This peptide is likely to serve as a spacer that is freed by cleavage during F maturation and is not found in the mature protein. The large number of changes may simply reflect the disposable nature of this sequence ([@B40]).

The NS2 protein may be important in modulating host innate immune responses ([@B41][@B42][@B43]) and may influence movement of infected cells ([@B44]). The NS2 showed an elevated level of evolutionary rate ([Fig. 4](#F4){ref-type="fig"}), consistent with a protein interacting with polymorphic host target proteins. Monitoring the local versus global protein changes in NS2 revealed multiple changes occurring in the amino-terminal domain and a portion of the domain important for TRAF3 interactions ([@B43]). The majority of changes in the Kilifi RSVA NS2 proteins were also observed in other parts of the world; however, the RSVB NS2 protein showed a significantly high degree of variation only observed in the Kilifi viruses ([Fig. 5C](#F5){ref-type="fig"}).

DISCUSSION {#sec4}
==========

The current work presents a functional approach for community-wide monitoring of RSV whole-genome genetic diversity suitable for detailed transmission studies. A challenge with deep sequencing of large sample sets of RNA viruses is the design of amplification primers. Traditionally, PCR primers were designed using alignments of sequences from the target virus; previous RSV studies with dideoxy sequencing used a greater number of tiled amplicons ([@B2], [@B24], [@B25], [@B38]) to cover the whole genome. With larger and more diverse sets, the alignment step becomes problematic. The approach described here bypasses the alignment step and was tailored for deep-sequencing methods. The RSV method uses only 6 amplicons to reduce the amplification costs and the required amount of input RNA. Although two primer sets were designed for RSVA and RSVB, the two sets can be pooled to simplify processing of samples of unknown RSV subtype. The computational methods used for primer selection facilitates updating of the primer sets as additional RSV genome sequence data become available. Frequent updating of these primer sets will help avoid sequence bias that could occur using antiquated primer sets. It is also important that the new full genomes reported here were assembled using *de novo* assembly methods. Although reference-based methods for assembling genomes from short-read data are rapid and less memory intensive, reference-based methods fail if a close reference genome is not available. The method presented here determines virus genomic sequences directly from patient material and shows sensitivity similar to that of traditional sequencing methods, but it avoids the potential virus selection that may occur if samples are first passaged through cell culture.

The 27 novel Kilifi RSV genomes (11 RSVA and 16 RSVB) generated in this study were used to assess local versus global RSV variety. Similar to the patterns previously observed with G ORF, the full genomic phylogenetic analysis confirmed that Kilifi genomes were interspersed with genomes from other countries, with rapid appearance of variants in Kilifi soon after they are first observed in other parts of the world ([@B45]). Kilifi RSV strains are similar to strains that circulate in other regions of the world and reveal only limited local evolution. Phylogenetic clustering appeared to be more influenced by time of virus sample collection than by geographical location, suggesting a fairly rapid global spread of novel RSV variants. It should also be noted that the similarity of the overall topology of phylogenetic trees from whole genomes and G sequences is encouraging and indicates that although full-genome sequences are most useful for detailed transmission studies, the relationships determined with the G region is similar to the patterns observed with the full-genome sequences.

The availability of full genomes allowed a comparison of estimates of the tMRCA of the Kilifi RSV strains. The obtained tMRCAs were broadly similar, although the higher evolutionary rates of the G region lead, as expected, to slightly later tMRCAs. The estimates based on the entire genomes lead to earlier dates and more discrete confidence intervals than estimates from specific genomic regions. Similar observations were made by Tan et al. ([@B22]).

Our comparison of genomes determined to be identical in the G region found nucleotide substitutions elsewhere in their genomes. The genomes with identical G regions invariably were from the same geographical region and over the same epidemic, the sample collection date interval ranging from a few days to months. This observation suggests that nucleotide substitution in the RSV genome in the short term is random, i.e., not concentrated in the regions that appear the most variable in the long term, and supports the use of whole-genome sequencing for monitoring viral transmission chains.

The observed sites of change in the G and F proteins were frequently in exposed regions of the proteins; several involved glycosylation site changes suggestive of immune evasion. In addition, similar to previous reports, the NS2 ([Fig. 5B](#F5){ref-type="fig"}) and M2-2 protein coding regions (not shown) were observed to change at rates higher than that for the full genome. Although these changes could be simply the allowed changes of unconstrained proteins, it is also possible that these sites are important for interacting with the host and may be under some pressure to change. Unfortunately, the sequence data set generated in this study was too small to provide statistically supported evidence of positive selection, but future studies with larger data sets will be facilitated by these methods.

The availability of a collection of RSV genome sequences from a single African location allowed a comparison of local versus global RSV evolution patterns. Important for vaccine design, the RSVA variants observed in a small region of Kenya appear to be in equilibrium with global variants. The same was not observed for RSVB. Possibly, RSVB variants may spread less efficiently, with a higher fraction of variants observed to be specific for Kilifi and not detected in other parts of the world. This pattern is consistent with RSVB as a less transmissible infection than RSVA ([@B4], [@B12]). However, there are fewer global sequences available for RSVB, so while the Kilifi RSVB variants appear to be unique, this could be a consequence of less surveillance and documentation of RSVB variation globally. Future work will help clarify this phenomenon, as it may have strong consequences on the efficacy of any RSV vaccine used locally.
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